No Data
No Data
Returns On Capital Are Showing Encouraging Signs At Fufeng Group (HKG:546)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasi
Fufeng Group (00546) will pay a final dividend of HK22 cents per share on June 28
Fufeng Group (00546) announced that the company will pay a final dividend of 22 per share on June 28, 2024...
FUFENG GROUP: POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 MAY 2024
Hong Kong Stock Concept Tracking | Beijing Pharmaceutical Documents Released! Regarding synthetic biology, brain-computer interface, etc., these companies have already laid out positions (with concept stocks)
The Zhitong Finance App learned that after the market on May 23, the General Office of the Beijing Municipal People's Government issued the “Beijing Action Plan to Accelerate Collaborative Innovation in Medicine and Health (2024-2026)” (Action Plan for short). The “Action Plan” is clear. By 2026, the total scale of the medical and health industry will reach 1.25 trillion yuan (of which the pharmaceutical industry's operating income will reach 240 billion yuan), and the fixed asset investment will be more than 10 billion yuan per year. It is worth noting that the action plan mentioned many new quality productivity examples such as synthetic organisms, genetic technology, and brain-computer interfaces. Meanwhile, at the Beijing Municipal Government Executive Meeting in March, research
Fufeng Group's (HKG:546) Shareholders Have More To Worry About Than Only Soft Earnings
The subdued market reaction suggests that Fufeng Group Limited's (HKG:546) recent earnings didn't contain any surprises. We think that investors are worried about some weaknesses underlying the earni
Fufeng Group Limited (HKG:546) Looks Inexpensive But Perhaps Not Attractive Enough
When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 10x, you may consider Fufeng Group Limited (HKG:546) as a highly attractive investment with its 4.1x P/E
No Data